Cargando…
The CloudUPDRS smartphone software in Parkinson’s study: cross-validation against blinded human raters
Digital assessments of motor severity could improve the sensitivity of clinical trials and personalise treatment in Parkinson’s disease (PD) but have yet to be widely adopted. Their ability to capture individual change across the heterogeneous motor presentations typical of PD remains inadequately t...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722731/ https://www.ncbi.nlm.nih.gov/pubmed/33293531 http://dx.doi.org/10.1038/s41531-020-00135-w |
_version_ | 1783620211974340608 |
---|---|
author | Jha, Ashwani Menozzi, Elisa Oyekan, Rebecca Latorre, Anna Mulroy, Eoin Schreglmann, Sebastian R. Stamate, Cosmin Daskalopoulos, Ioannis Kueppers, Stefan Luchini, Marco Rothwell, John C. Roussos, George Bhatia, Kailash P. |
author_facet | Jha, Ashwani Menozzi, Elisa Oyekan, Rebecca Latorre, Anna Mulroy, Eoin Schreglmann, Sebastian R. Stamate, Cosmin Daskalopoulos, Ioannis Kueppers, Stefan Luchini, Marco Rothwell, John C. Roussos, George Bhatia, Kailash P. |
author_sort | Jha, Ashwani |
collection | PubMed |
description | Digital assessments of motor severity could improve the sensitivity of clinical trials and personalise treatment in Parkinson’s disease (PD) but have yet to be widely adopted. Their ability to capture individual change across the heterogeneous motor presentations typical of PD remains inadequately tested against current clinical reference standards. We conducted a prospective, dual-site, crossover-randomised study to determine the ability of a 16-item smartphone-based assessment (the index test) to predict subitems from the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III (MDS-UPDRS III) as assessed by three blinded clinical raters (the reference-standard). We analysed data from 60 subjects (990 smartphone tests, 2628 blinded video MDS-UPDRS III subitem ratings). Subject-level predictive performance was quantified as the leave-one-subject-out cross-validation (LOSO-CV) accuracy. A pre-specified analysis classified 70.3% (SEM 5.9%) of subjects into a similar category to any of three blinded clinical raters and was better than random (36.7%; SEM 4.3%) classification. Post hoc optimisation of classifier and feature selection improved performance further (78.7%, SEM 5.1%), although individual subtests were variable (range 53.2–97.0%). Smartphone-based measures of motor severity have predictive value at the subject level. Future studies should similarly mitigate against subjective and feature selection biases and assess performance across a range of motor features as part of a broader strategy to avoid overly optimistic performance estimates. |
format | Online Article Text |
id | pubmed-7722731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-77227312020-12-09 The CloudUPDRS smartphone software in Parkinson’s study: cross-validation against blinded human raters Jha, Ashwani Menozzi, Elisa Oyekan, Rebecca Latorre, Anna Mulroy, Eoin Schreglmann, Sebastian R. Stamate, Cosmin Daskalopoulos, Ioannis Kueppers, Stefan Luchini, Marco Rothwell, John C. Roussos, George Bhatia, Kailash P. NPJ Parkinsons Dis Article Digital assessments of motor severity could improve the sensitivity of clinical trials and personalise treatment in Parkinson’s disease (PD) but have yet to be widely adopted. Their ability to capture individual change across the heterogeneous motor presentations typical of PD remains inadequately tested against current clinical reference standards. We conducted a prospective, dual-site, crossover-randomised study to determine the ability of a 16-item smartphone-based assessment (the index test) to predict subitems from the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III (MDS-UPDRS III) as assessed by three blinded clinical raters (the reference-standard). We analysed data from 60 subjects (990 smartphone tests, 2628 blinded video MDS-UPDRS III subitem ratings). Subject-level predictive performance was quantified as the leave-one-subject-out cross-validation (LOSO-CV) accuracy. A pre-specified analysis classified 70.3% (SEM 5.9%) of subjects into a similar category to any of three blinded clinical raters and was better than random (36.7%; SEM 4.3%) classification. Post hoc optimisation of classifier and feature selection improved performance further (78.7%, SEM 5.1%), although individual subtests were variable (range 53.2–97.0%). Smartphone-based measures of motor severity have predictive value at the subject level. Future studies should similarly mitigate against subjective and feature selection biases and assess performance across a range of motor features as part of a broader strategy to avoid overly optimistic performance estimates. Nature Publishing Group UK 2020-12-08 /pmc/articles/PMC7722731/ /pubmed/33293531 http://dx.doi.org/10.1038/s41531-020-00135-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Jha, Ashwani Menozzi, Elisa Oyekan, Rebecca Latorre, Anna Mulroy, Eoin Schreglmann, Sebastian R. Stamate, Cosmin Daskalopoulos, Ioannis Kueppers, Stefan Luchini, Marco Rothwell, John C. Roussos, George Bhatia, Kailash P. The CloudUPDRS smartphone software in Parkinson’s study: cross-validation against blinded human raters |
title | The CloudUPDRS smartphone software in Parkinson’s study: cross-validation against blinded human raters |
title_full | The CloudUPDRS smartphone software in Parkinson’s study: cross-validation against blinded human raters |
title_fullStr | The CloudUPDRS smartphone software in Parkinson’s study: cross-validation against blinded human raters |
title_full_unstemmed | The CloudUPDRS smartphone software in Parkinson’s study: cross-validation against blinded human raters |
title_short | The CloudUPDRS smartphone software in Parkinson’s study: cross-validation against blinded human raters |
title_sort | cloudupdrs smartphone software in parkinson’s study: cross-validation against blinded human raters |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722731/ https://www.ncbi.nlm.nih.gov/pubmed/33293531 http://dx.doi.org/10.1038/s41531-020-00135-w |
work_keys_str_mv | AT jhaashwani thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT menozzielisa thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT oyekanrebecca thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT latorreanna thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT mulroyeoin thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT schreglmannsebastianr thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT stamatecosmin thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT daskalopoulosioannis thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT kueppersstefan thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT luchinimarco thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT rothwelljohnc thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT roussosgeorge thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT bhatiakailashp thecloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT jhaashwani cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT menozzielisa cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT oyekanrebecca cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT latorreanna cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT mulroyeoin cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT schreglmannsebastianr cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT stamatecosmin cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT daskalopoulosioannis cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT kueppersstefan cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT luchinimarco cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT rothwelljohnc cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT roussosgeorge cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters AT bhatiakailashp cloudupdrssmartphonesoftwareinparkinsonsstudycrossvalidationagainstblindedhumanraters |